Inpixon (INPX) Reaches $2.35 1 Year Low; Catalyst Pharmaceutical Partners (CPRX) Sentiment Is 2

February 15, 2018 - By Marie Mckinney

The stock of Inpixon (NASDAQ:INPX) hit a new 52-week low and has $2.21 target or 6.00% below today’s $2.35 share price. The 9 months bearish chart indicates high risk for the $3.82 million company. The 1-year low was reported on Feb, 15 by Barchart.com. If the $2.21 price target is reached, the company will be worth $228,900 less. The stock decreased 25.72% or $0.8152 during the last trading session, reaching $2.3548. About 843,902 shares traded or 79.67% up from the average. Inpixon (NASDAQ:INPX) has declined 69.52% since February 15, 2017 and is downtrending. It has underperformed by 86.22% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $361.74 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and TouretteÂ’s disorder; and CPP-109 to treat TouretteÂ’s disorder.

Inpixon, through its subsidiaries, provides big data analytics and location based products and related services for the cyber-security and Internet of things markets worldwide. The company has market cap of $3.82 million. The firm operates through Mobile, IoT & Big Data Products; Storage and Computing; SaaS ; and Professional Services divisions. It currently has negative earnings. It offers AirPatrol, a location security and marketing platform for wireless and cellular devices to detect, monitor, and manage the content and behavior of smartphones, tablets, and other mobile devices based on their location and user; and Big Data appliance products.

Analysts await Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report earnings on March, 21. They expect $-0.06 EPS, down 20.00% or $0.01 from last year’s $-0.05 per share. After $-0.05 actual EPS reported by Catalyst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Broadfin Capital Llc holds 2.57% of its portfolio in Catalyst Pharmaceuticals, Inc. for 6.89 million shares. Tanaka Capital Management Inc owns 241,078 shares or 1.36% of their US portfolio. Moreover, Venbio Select Advisor Llc has 0.91% invested in the company for 4.64 million shares. The New York-based Knott David M has invested 0.39% in the stock. Berson & Corrado Investment Advisors Llc, a New York-based fund reported 95,100 shares.

The stock increased 1.73% or $0.06 during the last trading session, reaching $3.53. About 81,761 shares traded. Catalyst Pharmaceuticals, Inc. (CPRX) has risen 267.48% since February 15, 2017 and is uptrending. It has outperformed by 250.78% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Marie Mckinney

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: